Trial · NCT02970162
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Quantitative Myasthenia Gravis (QMG) Score | Amifampridine Phosphate | Baseline | 7.8 | Standard Deviation 4.20 | scores on a scale |
| Quantitative Myasthenia Gravis (QMG) Score | Placebo (for Amifampridine Phosphate) | Baseline | 8.5 | Standard Deviation 5.43 | scores on a scale |
| Quantitative Myasthenia Gravis (QMG) Score | Amifampridine Phosphate | Day 4 | 7.9 | Standard Deviation 4.94 | scores on a scale |
| Quantitative Myasthenia Gravis (QMG) Score | Placebo (for Amifampridine Phosphate) | Day 4 | 15.0 | Standard Deviation 5.90 | scores on a scale |
| Quantitative Myasthenia Gravis (QMG) Score | Amifampridine Phosphate | Change from baseline | 0.1 | Standard Deviation 3.07 | scores on a scale |
| Quantitative Myasthenia Gravis (QMG) Score | Placebo (for Amifampridine Phosphate) | Change from baseline | 6.5 | Standard Deviation 4.82 | scores on a scale |
| Subject Global Impression (SGI) Score | Amifampridine Phosphate | Baseline | 6.1 | Standard Deviation 0.86 | scores on a scale |
| Subject Global Impression (SGI) Score | Placebo (for Amifampridine Phosphate) | Baseline | 5.8 | Standard Deviation 0.90 | scores on a scale |
| Subject Global Impression (SGI) Score | Amifampridine Phosphate | Day 4 | 5.3 | Standard Deviation 1.65 | scores on a scale |
| Subject Global Impression (SGI) Score | Placebo (for Amifampridine Phosphate) | Day 4 | 2.4 | Standard Deviation 1.76 | scores on a scale |
| Subject Global Impression (SGI) Score | Amifampridine Phosphate | Change from baseline to Day 4 | -0.8 | Standard Deviation 1.74 | scores on a scale |
| Subject Global Impression (SGI) Score | Placebo (for Amifampridine Phosphate) | Change from baseline to Day 4 | -3.5 | Standard Deviation 2.18 | scores on a scale |
| Change in Clinician's Global Impression of Improvement (CGI-I) at Day 4 Compared to Baseline | Amifampridine Phosphate | 3.8 | Standard Deviation 0.8 | scores on a scale | |
| Change in Clinician's Global Impression of Improvement (CGI-I) at Day 4 Compared to Baseline | Placebo (for Amifampridine Phosphate) | 5.5 | Standard Deviation 1.27 | scores on a scale | |
| Triple Timed Up and Go Walk Test (3TUG) | Amifampridine Phosphate | 1 | Participants | ||
| Triple Timed Up and Go Walk Test (3TUG) | Placebo (for Amifampridine Phosphate) | 8 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02970162/results